( OTC-BB:UGNE )

News from unigene laboratories, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 14, 2013, 08:31 ET Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update

 Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the first quarter ended March 31, 2013 and provided a corporate...


May 09, 2013, 08:33 ET Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs

 Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design and development of peptide-based therapeutics, today announced it has entered...


Apr 17, 2013, 17:16 ET Victory Park Capital Completes Public Auction of Unigene's Peptelligence™ Drug Delivery Platform

 Unigene Laboratories, Inc. (PINK: UGNE), today announced that on April 16, 2013, Victory Park Capital Advisors, LLC (VPC) held a public...


Apr 08, 2013, 08:33 ET - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -

Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Mar 11, 2013, 19:12 ET Unigene Announces Fourth Quarter and Full-Year 2012 Results

Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the fourth quarter and full-year ended December 31, 2012 and provided...


Mar 06, 2013, 16:56 ET Unigene Comments on FDA Advisory Committee Review of Salmon Calcitonin

 Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Feb 13, 2013, 09:31 ET Unigene Receives 2013 Drug Delivery Partnerships Industry Achievement Award

 Unigene Laboratories, Inc. (PINK: UGNE) today announced that for the second year in a row it has received the Drug Delivery...


Feb 07, 2013, 08:33 ET Unigene to Present at the 17th Annual Drug Delivery Partnerships Meeting

 Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Jan 31, 2013, 17:16 ET Unigene Completes Financial Statement Amendment

Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Jan 15, 2013, 11:06 ET Unigene Welcomes FDA Advisory Committee Review of Salmon Calcitonin

Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Dec 12, 2012, 08:02 ET Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone

 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Dec 11, 2012, 08:02 ET Unigene Engages Financial Advisor to Explore Strategic Options and Advance Corporate Objectives

 Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has retained Canaccord Genuity to assist the Company with its exploration and...


Nov 27, 2012, 08:02 ET Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127

Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarix Pharmaceuticals today announced that the companies have entered into a definitive licensing...


Nov 20, 2012, 09:06 ET Unigene Announces Third Quarter 2012 Corporate Update

 Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a corporate review on key development programs and strategic initiatives, including...


Nov 16, 2012, 09:40 ET Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012

 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics,...


Oct 16, 2012, 08:58 ET Unigene's Licensee, Tarsa Therapeutics, Reports Positive Clinical Data in Phase 2 Study of Oral Calcitonin for Prevention of Postmenopausal Osteoporosis

 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Oct 15, 2012, 08:02 ET Unigene's Oral PTH Program Featured at ASBMR 2012 Annual Meeting

Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Sep 26, 2012, 08:32 ET Unigene to Target Partnering and Therapeutic Development Opportunities Following Victory Park Capital Debt Financing and Forbearance

Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the Company has entered into a Forbearance Agreement and First Amendment to Amended and...


Sep 20, 2012, 10:30 ET Unigene To Present at the 2012 Obesity Society's 30th Annual Scientific Meeting

 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today...


Sep 19, 2012, 08:02 ET Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127

 Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarix Pharmaceuticals today announced the successful completion of a feasibility study of an oral...


Aug 15, 2012, 08:10 ET Unigene And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treating Type 2 Diabetes

Unigene Laboratories, Inc. (OTCBB: UGNE) and Nordic Bioscience today announced, under the Companies' established Joint Development Vehicle (JDV),...


Aug 09, 2012, 08:06 ET Unigene Announces Second Quarter 2012 Financial Results

Unigene Laboratories, Inc. (OTCBB: UGNE) today announced financial results for the second quarter ended June 30, 2012 and provided a corporate...


Jul 26, 2012, 08:10 ET Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines

  Unigene Laboratories, Inc. (OTCBB: UGNE) today announced it has contacted relevant commercial parties to request access to certain...


Jun 28, 2012, 08:32 ET Unigene's Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences

 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based...


Jun 04, 2012, 08:31 ET Unigene Enters Agreement to Eliminate 1/3 of its Outstanding $67MM Debt

 Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the Company entered into a settlement and release agreement with the founding Levy...